I guess it would depend on the reason for denial to a patient. If it is solely because it isn't regulatory approved yet then that doesn't seem sufficient. If the drug was provided for free from the pharma company it would be a faster path to a human trial which would be a win/win for all involved with the only possible negative for a person who doesn't have anything to lose.